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Abstract
Alcoholic liver disease (ALD) is a leading cause of liver-related morbidity and mortality. ALD 
encompasses a spectrum of disorders ranging from asymptomatic steatosis, alcoholic 
steatohepatitis (ASH), fibrosis, cirrhosis and its related complications. Moreover, patients can 
develop an acute-on-chronic form of liver failure called alcoholic hepatitis (AH). Most patients are 
diagnosed at advanced stages of the disease with higher rates of complications and mortality. The 
mainstream of therapy of ALD patients, regardless of the disease stage, is prolonged alcohol 
abstinence. The current therapeutic regimens for AH (i.e. prednisolone) have limited efficacy and 
targeted therapies are urgently needed. The development of such therapies requires translational 
studies in human samples and suitable animal models that reproduce clinical and histological 
features of AH. In recent years, new animal models that simulate some of the features of human 
AH have been developed, and translational studies using human samples have identified potential 
pathogenic factors and histological parameters that predict survival. In this review, we discuss the 
pathogenesis and management of ALD, focusing on AH, its current therapies and potential 
treatment targets.
1. ALCOHOLIC LIVER DISEASE: GENERAL CONCEPTS
Alcohol use disorders account for a significant cause of preventable disease worldwide, with 
resultant alcoholic liver disease (ALD) causing significant liver-related morbidity and 
mortality among adults with prolonged alcohol abuse1. ALD represents half of the cases of 
liver cirrhosis, therefore, making it the dominant cause of advanced liver disease globally2. 
The diagnosis of ALD is usually made at advanced stages of disease with higher rates of 
complications and mortality1. Early detection of initial forms of ALD in the primary care 
setting and subsequent behavioral interventions should be encouraged. However, there is a 
lack of characterization of the early stages of ALD in humans. Moreover, there is a clear 
need to define the natural history and prognostic factors as well as to develop reliable non-
invasive markers for ALD.
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The management of patients with ALD has evolved little due to many factors including 
difficulties of conducting clinical trials in patients with an active alcohol addiction, the lack 
of interest from drug companies, public funding for research and the drawbacks of existing 
experimental models. As a consequence, there are not approved targeted therapies to treat 
patients with severe ALD3. The development of such therapies requires translational studies 
in human samples and suitable animal models that reproduce clinical and histological 
features of alcoholic hepatitis (AH). In recent years, new animal models that simulate some 
of the features of human AH have been developed, and translational studies using human 
samples have identified potential pathogenic factors and histological parameters that predict 
survival3, 4.
2. ENVIRONMENTAL AND GENETIC FACTORS
The susceptibility to develop ALD among heavy drinkers depends on genetic and 
environmental factors. At similar levels of ethanol consumption, some patients only develop 
macrovesicular steatosis, while others develop progressive fibrosis and cirrhosis. Although a 
positive correlation between cumulative alcohol intake and degrees of liver fibrosis has been 
reported, extensive variability in the histological response to alcohol abuse exists in 
individuals5. The environmental risk factors identified as promoters for the progression of 
ALD in patients with alcohol abuse include sex, obesity, drinking patterns, dietary factors, 
non-sex-linked genetic factors, and cigarette smoking6-8.
Epidemiological studies suggest that several genetic factors influence the severity of 
steatosis and oxidative stress, and that the cytokine milieu, the magnitude of immune 
response and the severity of fibrosis also modulate an individual's propensity to progress to 
advanced ALD9. Genes encoding the main alcohol metabolizing enzymes and proteins 
involved in the toxic effects of alcohol and its metabolites on the liver, such as antioxidants 
and pro-inflammatory cytokines, have been the focus of investigation8. Genetic factors that 
influence the activity of these enzymes and the rate of alcohol metabolism have been 
studied. Variations in the rate of generation of acetaldehyde, a promoter of fibrogenesis, 
could explain the differences in the susceptibility of individuals to ALD from alcohol abuse. 
Although polymorphisms in the genes encoding the main alcohol-metabolizing enzymes 
such as ADH, ALDH and CYP2E1 are accepted to be involved in an individual's 
susceptibility to alcoholism, their role in the progression of ALD remains controversial10. 
Recent studies indicate that variations in the patatin-like phospholipase domain-containing 
protein 3 (PNPLA3) are strongly associated with increased risk of ALD. PNPLA3 
polymorphisms can be considered as the only confirmed and replicated genetic risk factor 
for ALD. Future studies would clarify the role of PNPLA3 and identify it as a target for 
therapy11-13. Despite the large number of studies that have assessed the role of genetic 
variation in susceptibility to ALD, a large-scale, well-designed, genome wide association 
study of factors associated with ALD remains to be performed. Consequently, a genetic test 
capable of identifying which patients are susceptible to advanced ALD is yet to be 
developed3.
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3. DISEASE SPECTRUM AND PATHOGENESIS
ALD comprises different stages of liver disease as a result of susceptibility factors and 
duration of alcohol abuse. These stages include steatosis, alcoholic steatohepatitis (ASH), 
progressive fibrosis, cirrhosis, decompensated cirrhosis and superimposed hepatocellular 
carcinoma (HCC) (Figure 1). Patients with underlying cirrhosis and ongoing alcohol abuse 
are predisposed to developing AH14, 15. With a mortality rate of 30-50% at 3 months15, AH 
represents one of the deadliest diseases in clinical hepatology.
Steatosis is defined histologically as the deposition of fat in hepatocytes. Alcohol intake 
increases NADH/NAD+ in hepatocytes, thereby disrupting fatty acid oxidation16. Increased 
fatty acid and triglyceride synthesis, hepatic influx of free fatty acids from adipose tissue 
and chylomicrons from the intestinal mucosa, results in increased hepatic lipogenesis, 
decreased lipolysis, and mitochondrial and microtubule damage17. Up to 90% of patients 
with heavy alcohol intake have some degree of steatosis18, which is usually asymptomatic 
and rapidly reversible with abstinence.
Continued heavy alcohol consumption leads to ASH, characterized by polymorphonuclear 
(PMN) cell infiltration and hepatocellular damage. Acetaldehyde, a byproduct of alcohol 
metabolism, is implicated for the hepatocellular injury. It binds proteins and DNA, forming 
adducts that promote glutathione depletion, lipid peroxidation and mitochondrial 
damage19, 20.
Sustained alcohol misuse causes progression to liver fibrosis and cirrhosis, which leads to a 
high risk of complications (such as ascites, variceal bleeding, hepatic encephalopathy, renal 
failure and bacterial infections)21, 22. Acetaldehyde promotes fibrogenesis directly by 
increasing the expression of collagen in hepatic stellate cells (HSC)23, 24. HSCs can also be 
activated by neutrophils, damaged hepatocytes, and activated Kupffer cells through various 
pro-fibrogenic mediators including transforming growth factor β, platelet-derived growth 
factor, IL-8, angiotensin II and leptin25. The activation and biological actions of these 
mediators are largely due to reactive oxygen species (ROS)26. Alcohol abuse contributes to 
dysbiosis and inflammation of the intestinal tract with resulting translocation of microbial 
products such as lipopolysaccharide (LPS) to the liver27. LPS targets toll-like receptor-4 
(TLR4) signaling in HSCs and sinusoidal endothelial cells, resulting in HSC activation and 
promotion of fibrogenesis through regulation of angiogenesis28.
4. ALCOHOLIC HEPATITIS
AH is a clinical syndrome characterized by new onset jaundice and/or ascites in the setting 
of ongoing alcohol abuse and underlying ALD14. Patients typically present with rapidly 
progressive jaundice, which can be accompanied by fever, abdominal pain, anorexia, and 
weight loss. In some cases, portal hypertension is severe, and the patient presents with 
ascites, encephalopathy, or variceal bleeding. Alcohol use history can be quite variable. 
Often, there is a history of daily heavy alcohol use, which may have escalated in the weeks 
and months prior to presentation. Alternatively, as patients begin feeling ill, they may reduce 
or discontinue alcohol use in the preceding days or even weeks. Physical exam findings are 
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nonspecific, and may include fever, tender hepatomegaly, ascites, muscle wasting, and other 
stigmata of chronic liver disease.
The diagnosis of AH is made on clinical grounds, based on a history of excessive alcohol 
use with the typical physical exam and laboratory findings. Other potential causes of Acute 
Hepatitis such as viral, drug-induced liver injury, spontaneous bacterial peritonitis (SBP) or 
other infections should be considered and ruled out. Imaging is important to exclude biliary 
or vascular disorders and to evaluate for co-existing hepatocellular carcinoma. In many 
patients with ALD and clinical complications, the presence of a superimposed AH is not 
explored and therefore its real incidence is unknown. Population based studies using 
administrative data estimate approximately 4.5 hospitalizations for AH per 100,000 persons 
each year, with a slight male predominance29. Prospective studies assessing the incidence, 
risk factors and clinical features of AH are clearly needed.
The Maddrey's discriminant function (DF) is one of several models that have been developed 
to help predict outcomes of patients with AH and to guide therapy. A DF value ≥ 32 is 
indicative of a high risk of short-term mortality (35% at 1 month) and is the basis for patient 
selection for specific therapy with corticosteroids. Additional predictive models include the 
Model for End-Stage Liver Disease (MELD), the Glasgow AH score, the ABIC score, and 
the Lille model.
Patients that develop severe AH usually require hospitalization for initial management. 
Primary prevention is aimed at alcohol abstinence; active management of alcohol use 
disorders is critical to achieving continued abstinence. For the successful management of 
these patients, a multidisciplinary team composed of hepatologists, psychologists, 
psychiatrists and social workers is highly recommended29. Significant protein calorie 
malnutrition and vitamin and mineral deficiencies including vitamin A, vitamin D, thiamine, 
folate, pyridoxine, and zinc is common6, 30, 31. Nutritional support improves liver function 
and short-term follow-up studies suggest that improved nutrition might improve survival 
times and histological findings in patients with AH32. Most patients improve spontaneously 
with abstinence and supportive care. Medical treatment is considered for patients who 
present with a very severe clinical picture or continue to deteriorate.
The management of AH depends on the severity of the episode (Fig. 2). Severe AH 
requiring medical intervention is defined as a Maddrey's discriminant function >32, MELD 
>21, ABIC >6.9 or Glasgow >83. Both the AASLD and EASL practice guidelines 
recommend the use of corticosteroids (i.e. prednisolone 40 mg daily for 4 weeks) for 
patients with severe AH6, 33. Moreover, clinical practice guidelines recommend stopping 
corticosteroids after one week in those with an unfavorable Lille score, as the risks of 
continued therapy likely outweigh the benefits. When considering treatment with 
corticosteroids, patients require careful monitoring for evidence of present or developing 
infections and/or active GI bleeding.
Pentoxifylline is a phosphodiesterase inhibitor that inhibits the synthesis of tumor necrosis 
factor, which is increased in patients with AH. In practice, pentoxifylline was typically 
reserved as a second-line agent for patients with contraindications to corticosteroid therapy. 
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The recent STOPAH trial, comparing prednisolone and pentoxifylline, has proven to be a 
definitive study for assessing the efficacy of these drugs for AH34. Current consensus 
regarding pentoxifylline is that it is not effective rescue therapy in patients who do not 
respond to corticosteroids.
The anti-TNF agents, Infliximab and etanercept, were also investigated as potential therapies 
for patients with AH. TNF alpha was theorized as a key culprit in potentiating hepatocyte 
inflammation. Studies did not support the hypothesis35 and instead demonstrated adverse 
side effects such as increased rates of infection and increased mortality. Presently anti-TNF-
α agents are not recommended for treatment of AH36.
N-acetylcysteine replenishes glutathione in damaged hepatocytes and prevents cell death in 
ALD. A recent randomized trial performed using a combination of N-acetylcysteine with 
prednisolone showed a clear trend to improve survival, with decreased 1-month mortality 
(8% vs. 24%) and reduced incidence of hepatorenal syndrome and infection. The study, 
however, was underpowered to reach statistical significance and was found to have no effect 
on six-month survival and primary outcome37. Its favorable safety profile renders N-
acetylcysteine a potential option, in combination with corticosteroids, for patients with 
severe disease.
5. NEW MOLECULAR TARGETS TO TREAT ALCOHOLIC HEPATITIS
Cell death via apoptosis
Alcoholic hepatitis results in massive hepatocyte cell death and apoptosis is a prominent 
feature of many of the preceding stages of alcoholic liver disease. Since caspase inhibitors 
are known to inhibit apoptosis, animal studies, in models of chronic liver injury from viral 
hepatitis secondary to hepatitis C infection, and non-alcoholic steatohepatitis, using caspase 
inhibitors and have shown promising results in ameliorating liver injury and impeding 
progression to fibrosis38-40. It is reasonable to think such an approach would work in 
alcoholic liver disease, in particular in alcoholic hepatitis.
Role of Innate Immune System
Following activation, neutrophils undergo transmigration into the liver parenchyma where 
they destroy damaged hepatocytes through the release of ROS and proteases, supporting 
their prominent role in ALD41. IL-17 is increased in patients with alcoholic hepatitis and 
directly induces neutrophil recruitment, but also indirectly promotes neutrophil recruitment 
by stimulating HSCs to secrete IL-8 and CXCL142, 43. This suggests that the modification of 
these chemokines, or their precursors or activators, may mediate neutrophil infiltration and 
perhaps attenuate alcoholic hepatitis. The role of CXCL family of chemokines has been 
examined in translational studies, and discovered that elevated levels correlate with severity 
of disease, degree of portal hypertension, and patient survival35, 44. Given these promising 
findings, therapeutic agents that target CXC chemokines may be considered in the treatment 
of AH. Osteopontin is an extracellular matrix protein that is markedly upregulated in 
alcoholic hepatitis, similar to other CXCL chemokines45. Osteopontin inhibitors, therefore, 
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are also attractive potential new therapeutic agents. The redundancy of chemokines and their 
receptors makes the development of targeted therapeutics challenging.
Instigators of inflammation are also thought to play an important role. Sources of 
inflammatory mediators can be classified as sterile, originating from intracellular sources, or 
microbiological, from bacterial translocation in the gut. Damage-associated molecular 
patterns (DAMPs) are intracellular molecules released by dying cells that trigger the innate 
immune system46. Among the DAMPs, high mobility group box-1 (HMGB-1) has been 
implicated in the development of alcoholic steatohepatitis45, and likely also has a role in 
alcoholic hepatitis. Gut-derived bacterial products belong to the class of pathogen-associated 
molecular patterns (PAMPs). These PAMPs circulate through the portal circulation and 
induce an inflammatory response through activation of HSCs and Kupffer cells47, 48. 
Protecting against gut leakage could be a potential target for therapy aimed at preventing the 
initiation of the innate immune response in alcoholic hepatitis.
Role of the Adaptive Immune System
It is well-known that the adaptive immune system responds to oxidative stress and 
peroxidation adducts, but its role in hepatocellular damage and inflammation in alcoholic 
hepatitis remains unknown. As previously described, increased alcohol consumption 
generates ROS through multiple mechanisms and leads to adduct formation; protein adducts 
have altered conformation and function, and are relatively immunogenic. Patients with 
alcoholic hepatitis have been found to have circulating T cells with antibodies to these 
adducts, enforcing that the adaptive immune response likely plays a large, yet undiscovered 
role in AH49-52.
Targeting dysbiosis
Alterations in the gut microbiome has unique implications on the development of alcoholic 
hepatitis, this was first suggested in the intragastric mouse feeding model in which elevated 
serum ethanol levels were maintained, treated mouse populations were observed to have 
both microbial translocation and dysbiosis53. In studies involving patients with chronic 
alcoholic liver disease, administration of probiotics appeared to improve liver function in 
this patient group, further supporting that the intestinal bacterial milieu is of great 
importance54. Work examining the applicability of probiotics in patients with alcoholic 
hepatitis is still underway. Other genomic and metabolomic analyses of intestinal bacteria 
revealed low levels of lactobacilli and reduced production of saturated long chain fatty acids 
(LCFA). In this model, supplementation with LCFA restored eubiosis, intestinal barrier 
function, and reduced liver injury in mice55, suggesting a role for potential supplementation 
of LCFA in this patient group.
The role of hepatocyte proliferation and regeneration
Hepatic regeneration in the healthy liver results from expansion of the remaining healthy 
hepatocytes. In the diseased state, in which hepatocyte proliferation is inhibited, pluripotent 
liver progenitor cells, also referred to as oval cells, or ductal hepatocytes, proliferate and 
differentiate to repopulate hepatocytes or biliary epithelial cells56. In the rodent model, 
alcohol attenuates regeneration of hepatocytes following partial surgical hepatectomy57, so 
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despite a lack of human studies, it is reasonable to hypothesize that alcohol not only causes 
hepatocellular injury and death, but also prevents regeneration. While histologically, the 
presence of bilirubinostasis and severe fibrosis are associated with a poorer prognosis in 
alcoholic hepatitis, the presence of proliferating hepatocytes is associated with better 
prognosis58. In addition, intense neutrophilic infiltrate was also associated with better 
prognosis56, suggesting that cytokines released by neutrophils likely play a role in hepatic 
regeneration following cessation of alcohol, and that resolving inflammation may actually 
have a beneficial, rather than detrimental role in alcoholic liver disease, contributing to 
hepatic regeneration (Table 1). Severe alcoholic hepatitis is marked by a failure of liver 
progenitor cells to progress past massive proliferation to maturation into mature 
hepatocytes59, the mechanism for which remains to be elucidated (Figure 3). Potential 
therapeutic agents to promote hepatic regeneration are being explored.
6. CONCLUSIONS AND PROSPECTS FOR FUTURE
Alcohol consumption is a leading cause of global morbidity and mortality, with much of its 
negative impact as a result of ALD. The lack of characterization of the early stages of ALD 
accounts for diagnoses being made at advanced stages of disease with higher rates of 
complications and mortality. Emphasis on better defining the natural history and prognostic 
factors and developing reliable non-invasive markers for ALD is required. Early detection of 
initial forms of ALD in the primary care setting and subsequent behavioral interventions 
would address this need.
Despite some important advances in our understanding of the pathogenesis and clinical 
characteristics of ALD, there have been no significant advances in therapy in the last 40 
years. The mainstream of therapy for patients with ALD, regardless of the disease stage, is 
prolonged alcohol abstinence. Abstinence is associated with improved clinical outcomes 
throughout the spectrum of ALD, from the asymptomatic early to the complicated severe 
cases. Clinical endpoints depend on the stage of ALD. In compensated patients, the 
endpoints consist of normalization of abnormal lab tests and reduction of liver fibrosis. 
These endpoints can be monitored non-invasively. The incidence of AH, one of the deadliest 
diseases, is unknown. Supportive therapy is the mainstay of treatment and current medical 
interventions are largely limited and ineffective. In patients with AH and decompensated 
cirrhosis, the clinical endpoints are survival and compensation of the liver disease. The 
molecular and cellular factors that influence AH are not completely known. Recent 
translational work using human liver tissue has been informative in identifying some 
potential therapeutic targets for severe AH. However, translation of these findings into novel 
therapies has been lacking. Additional detailed studies of these potential targets in humans 
and animal models are urgently needed to improve outcomes in this patient population.
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Abbreviations
ALD alcoholic liver disease
ASH alcoholic steatohepatitis
AH alcoholic hepatitis
ADH alcohol dehydrogenase
ALDH acetaldehyde dehydrogenase
CYP2E1 Cytochrome P450 2E1
PNPLA3 patatin-like phospholipase domain-containing protein 3
HCC hepatocellular carcinoma
NADH Nicotinamide adenine dinucleotide
PMN Polymorphonuclear leukocytes
HSCs hepatic stellate cells
ROS reactive oxygen species
LPS lipopolysaccharide
TLR4 toll-like receptor-4
SBP spontaneous bacterial peritonitis
DF Maddrey Discriminant Function
MELD model for end-stage liver disease
GAHS Glasgow Alcoholic Hepatitis Score
ABIC Age, Bilirubin, INR, Creatinine
AASLD American association for the Study of Liver Disease
EASL European Association for the Study of the Liver
TNF tumor necrosis factor
IL interleukin
CXCL1 chemokine (C-X-C motif) ligand 1
DAMP damage-associated molecular pattern
HMGB1 high mobility group box-1
PAMP pathogen-associated molecular pattern
LCFA long chain fatty acids
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Figure 1. 
Natural progression along the spectrum of ALD, from steatosis, to the inflammatory state of 
steatohepatitis, to progressive fibrosis and cirrhosis, and finally, to decompensated cirrhosis 
and hepatocellular carcinoma (HCC). Exacerbations of alcoholic hepatitis (AH) occur at 
many of the later stages of disease. Predisposing risk factors to accelerated progression are 
listed.
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Figure 2. 
Clinical evaluation for a patient with high suspicion of alcoholic hepatitis (AH) involves 
ruling out precipitating factors of decompensated liver disease and confounding illnesses. 
Role of transjugular liver biopsy is dependent on the availability in the center and the 
presence of potential confounding factors. Besides general measures, patients with severe 
episodes of AH should be treated with prednisolone (40 mg/day for 4 weeks). At week 1 the 
efficacy of prednisolone therapy should be evaluated using the Lille Score 
(www.Lillescore.com).
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Figure 3. 
Prognostic role of the accumulation of progenitors cells (cytokeratin-7 postive ductular cells) 
in patients with alcoholic hepatitis (AH). With permission from Sancho-Bru et al59.
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Table 1
Alcoholic Hepatitis Histological Score (AHHS) for Prognostic Stratification of Alcoholic Hepatitis56.
Points
Fibrosis stage AHHS categories (0-9 points)
    None Fibrosis or Portal fibrosis 0 Mild : 0-3
    Expansive fibrosis 0 Intermediate: 4-5
    Bridging fibrosis or Cirrhosis +3 Severe: 6-9
Bilirubinostasis
    None 0
    Hepatocellular only 0
    Canalicular or ductular +1
    Canalicular or ductular plus Hepatocellular +2
PMN infiltration
    Mild PMN Infiltration +2
    Severe PMN Infiltration 0
Megamitochondria
    No Megamitochondria +2
    Megamitochondria 0
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